Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04552743 · OUTCOME

Infusion-related Toxicities

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma · Source last updated 2022-09-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
adverse events
Interval / dispersion
Not reported
Time frame
7 days after mobilization procedure

What was measured

Infusion-related toxicities are adverse events considered at least possibly-related to the study treatments MGTA-145, assessed from Baseline to 7 days after mobilization. The outcome is reported as a listing of the preferred terms for the "at least possibly-related" adverse events, with outcome being the number of adverse events of that preferred term. The outcome is a listing of numbers without dispersion.

Groups in this outcome

Number of Events

Number of adverse events by preferred term experienced by participants receiving MGTA-145 and Plerixafor

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Number of Events25

Reported measurements

Pain
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events11Not reportedNot reportedNot reportedNot reported
Aspartate/alanine aminotransferase increase
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events1Not reportedNot reportedNot reportedNot reported
Nausea
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events2Not reportedNot reportedNot reportedNot reported
Headache
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events1Not reportedNot reportedNot reportedNot reported
Hyperhidrosis
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events1Not reportedNot reportedNot reportedNot reported
Low platelet count
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events2Not reportedNot reportedNot reportedNot reported
Vomiting
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events1Not reportedNot reportedNot reportedNot reported
Poor Graft Function (beyond 7 days post-mobilization)
Values in adverse events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Number of Events1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Pain
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Aspartate/alanine aminotransferase increase
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Nausea
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Headache
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Hyperhidrosis
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Low platelet count
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Vomiting
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Poor Graft Function (beyond 7 days post-mobilization)
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Infusion-related toxicities are adverse events considered at least possibly-related to the study treatments MGTA-145, assessed from Baseline to 7 days after mobilization. The outcome is reported as a listing of the preferred terms for the "at least possibly-related" adverse events, with outcome being the number of adverse events of that preferred term. The outcome is a listing of numbers without dispersion.
groups
  1. description
    Number of adverse events by preferred term experienced by participants receiving MGTA-145 and Plerixafor
    id
    OG000
    title
    Number of Events
param Type
NUMBER
reporting Status
POSTED
time Frame
7 days after mobilization procedure
title
Infusion-related Toxicities
type
SECONDARY
unit Of Measure
adverse events

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice